Frederick, Maryland13 days ago
Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix Research and Development Center is seeking an experienced Scientist with expertise in novel animal model development for immunologic and infectious diseases, oncology, biological and vaccine development in order to advance the pipeline of novel therapeutics and vaccines in Tonix’s preclinical research portfolio.